CTAD Conference

Clinical Trial Alzheimer’s Disease (CTAD) Conference

The CTAD was founded in 2008 by academics, Jacques Touchon, MD, PhD, Professor of neurology, Dean of the Montpellier Medical School and Bruno Vellas, MD, PhD, Professor of internal medicine and geriatrics, both working in the Alzheimer’s disease field.

The aim of the conference is to bring together academic and industry leaders to develop the most accurate clinical trials in Alzheimer’s disease to demonstrate the efficacy of drugs in development.

In order to concentrate on being a platform for scientific research, the conference accepts unrestricted grants from industry and non-profit organizations but does not allow industry-sponsored symposia or commercial exhibition. Abstracts for oral communications and poster presentations are submitted to an international, scientific committee for peer-review. Physicians and scientists, from academic and industry research centers are invited to submit.

Proceedings are published in the JPAD, Journal of Prevention of Alzheimer’s Disease, and are accessible to all in free access https://www.springer.com/journal/42414 after the CTAD conference to allow the medical and scientific community to benefit from the new findings presented at the CTAD conference.

Paul Aisen, MD, ATRI, USC, San Diego, Mike Weiner, MD, UCSF, San Francisco, Lefkos Middelton, MD, PhD, Imperial College London and Merce Boada, MD, Fundacio ACE, Barcelona joined the CTAD scientific leadership team.

The CTAD conference is organized once a year in the United States or in Europe.

CTAD and JPAD publishers do not assume any responsibility for the content of the posters or presentations, which are selected according to a grid of objective criteria, elaborated by a committee of renowned experts, who leave the authors the full responsibility for their content. They do not make any judgement on the legal or even more, judicial plans, which exceed our competences and do not wish to enter into any exchange on this plan. They do act as a scientific "platform" and therefore, are very careful about neutrality and objectivity. They do not cope with any cause and do not wish to give any echo to polemics that do not concern them 

The CTAD conference is managed by CTAD Congress SAS and ANT Event international SAS registered in Montpellier. CTAD participates to donations to research and medical non-profit organizations.